Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05967416 · ClinicalTrials.gov registry record · Phase 1
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, sponsored by SIRPant Immunotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT05967416 is a Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma that is actively recruiting participants, run by SIRPant Immunotherapeutics. The registered enrollment target is 24 participants, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05967416, a Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by SIRPant Immunotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.
Conditions Studied
Interventions
- BIOLOGICAL SIRPant-M
- RADIATION External-beam radiotherapy (XRT)
Study Locations (3)
California
- City of Hope - Duarte
New Jersey
- Hackensack University Medical Center - Hackensack
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-17 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05967416
The ClinicalTrials.gov registry entry for NCT05967416 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (75% lower). The listed sponsor is SIRPant Immunotherapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which SIRPant-M is the first listed.
NCT05967416 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT05967416 about?
NCT05967416 is a clinical study titled "Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma". The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims...
What is the current status of trial NCT05967416?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-01-17. Estimated completion is 2025-12.
What conditions does trial NCT05967416 study?
This clinical trial studies the following conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05967416?
The interventions under investigation include: SIRPant-M (BIOLOGICAL), External-beam radiotherapy (XRT) (RADIATION).
Who is sponsoring clinical trial NCT05967416?
This trial is sponsored by SIRPant Immunotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05967416 being conducted?
This trial has 3 study locations across California, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
SynKIR-310 for Relapsed/Refractory B-NHL
RECRUITING · Phase 1
-
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
RECRUITING · Phase 1
-
Study of LYL314 in Aggressive Large B-Cell Lymphoma
RECRUITING · Phase 1
-
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
Explore more on PlainTrial
Refractory Non-Hodgkin Lymphoma
All registered trials for this condition
Relapsed Non-Hodgkin Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.